STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3617 by analyst upside · 2026-06-21
KALV
KalVista Pharmaceuticals Inc
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+0.0%
implied upside to consensus target
Current Price $27.0
Consensus Target $27.0
Bull Target $27.0
Bear Target $27.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
0
Sell
0
52-Week Low $9.83
52-Week High $27.0
YTD Return +74.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E 17.5x
EPS (TTM) $-3.94
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $114M
Profit Margin -118.7%
52-WEEK RANGE
52-Week Low $9.83
52-Week High $27.0
Current Price $27.0
Bear Target $27.0
Bull Target $27.0
● Now $27.0 ● Target $27.0
TRADING DATA
Avg Volume 3.6M
YTD Return +74.6%
Analyst Count 3
Consensus Buy
Upside to Target +0.0%
Last Updated 2026-06-21

ANALYST SUMMARY

KalVista Pharmaceuticals Inc (KALV) is currently trading at $27.0 with a Wall Street consensus price target of $27.0, implying potential upside of 0.0% over the next 12 months. 3 analysts currently cover KALV, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $27.0, while the most cautious has a target of $27.0.

KALV operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 74.6% year-to-date and is currently trading near the upper end of its 52-week range of $9.83 – $27.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KALV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-05-01 31% win rate (48 calls)
Needham ↓ Downgrade
Buy → Hold 2026-04-30 20% win rate (5 calls)
Stifel — Reiterated
Buy → Buy 2026-03-26 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-03-26 Building track record
Needham — Reiterated
Buy → Buy 2026-03-25 20% win rate (5 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-01-09 31% win rate (48 calls)
Needham — Reiterated
Buy → Buy 2026-01-09 20% win rate (5 calls)
Needham — Reiterated
Buy → Buy 2026-01-06 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
11/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →